Generics major Viatris (Nasdaq: VTRS) yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences.
The decision was welcomed by investors as the company’s shares leapt more than 13% to $10.97. Oyster Point did even better, with its shares leaping 38.6% to $11.57.
Together, the two acquisitions have an aggregate purchase price of around $700-$750 million, which Viatris expects to fund with cash on hand.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze